Welcome to our dedicated page for Treace Medical Concepts news (Ticker: TMCI), a resource for investors and traders seeking the latest updates and insights on Treace Medical Concepts stock.
Treace Medical Concepts, Inc. (TMCI) is a leader in 3D bunion correction and foot/ankle surgical solutions, delivering innovative technologies like the Lapiplasty system. This page provides timely updates on TMCI’s advancements in orthopedic medical devices, financial milestones, and clinical research.
Access press releases covering product launches, regulatory approvals, and partnerships that shape surgical practices. Investors will find earnings reports and strategic updates, while medical professionals can track procedural innovations and training opportunities.
Our curated news collection ensures you stay informed about TMCI’s contributions to reproducible surgical outcomes and cost-effective patient care. Content is verified for accuracy and relevance, offering a neutral perspective on company developments.
Bookmark this page for streamlined access to TMCI’s latest achievements in addressing complex deformities through evidence-based solutions. Regularly updated to reflect the company’s commitment to advancing orthopedic care.
Treace Medical Concepts (TMCI), a medical technology company specializing in bunion and midfoot deformity surgical treatments through its Lapiplasty® and Adductoplasty® Procedures, has scheduled its first quarter 2025 financial results announcement for May 8, 2025, after market close.
The company will host a conference call at 4:30 pm ET to discuss the results. Interested investors can participate by registering to receive dial-in numbers and a unique pin. A live and archived webcast will be available on the company's investor relations website at https://investors.treace.com/.
Treace Medical Concepts (NASDAQ: TMCI) announced a significant leadership transition as CEO and Founder John T. Treace will assume the role of Chairman of the Board following the 2025 annual stockholders meeting on May 20, 2025. He will succeed James T. Treace, who will retire from the Board after serving as Chair since the company's inception in 2014.
John T. Treace will maintain his position as CEO while taking on the Chairman role. Richard W. Mott will continue serving as lead independent director. The company, known for its Lapiplasty® and Adductoplasty® Procedures in bunion treatment, expressed commitment to delivering additional innovations and expanding its bunion portfolio to drive market penetration throughout 2025 and beyond.
Treace Medical Concepts (NASDAQ: TMCI) presented updated clinical data for its bunion and midfoot deformity treatments at the 2025 ACFAS Conference. The company showcased results from three key studies:
The ALIGN3D™ study (135 patients, 4-year follow-up) showed early weight bearing at 8.4 days and low recurrence rates of 0.8% (HVA>20°). The Mini3D™ study (75 patients, 1-year follow-up) demonstrated weight bearing at 7.9 days with 0% recurrence (HVA>20°). The MTA3D™ study (18 patients, 1-year follow-up) reported weight bearing at 7.5 days with significant improvements in both midfoot and bunion deformity correction.
All studies showed significant improvements in pain and patient-reported outcomes. Additional retrospective data from 43 patients undergoing Adductoplasty® and Lapiplasty® procedures showed positive clinical results over a 17.7-month follow-up period.
Treace Medical Concepts (TMCI) announced new technological innovations to be showcased at the 2025 ACFAS Annual Scientific Conference in Phoenix, Arizona. The company introduced several advancements in their bunion treatment portfolio, including:
- Micro-Lapiplasty™ and Mini-Adductoplasty™ platforms with SpeedPlate™ MicroQuad™ implant for small incision approaches
- Two new 3D minimally invasive systems: Nanoplasty™ and Percuplasty™, complemented by SpeedAkin™ implant
- SpeedMTP™, combining SpeedPlate™ compression fixation with Fastpitch™ locking screws for arthritic great toe joint treatment
- IntelliGuide™ PSI cut guides, offering pre-op planning, patient-specific 3D-printed guides, and Bone Clone™ anatomic foot models
Treace Medical Concepts (TMCI) reported its Q4 and full-year 2024 financial results, showing continued growth and improved profitability. Q4 2024 revenue increased 10% to $68.7 million, while full-year revenue grew 12% to $209.4 million.
The company significantly reduced its Q4 net loss to ($0.5) million from ($6.3) million in Q4 2023, with Adjusted EBITDA improving 322% to $11.1 million. Full-year 2024 net loss was ($55.7) million.
Key operational highlights include:
- Added 280 new active surgeons in 2024, reaching 3,135 total (10% increase)
- Expanded patent portfolio to 97 granted patents
- Entered high-volume osteotomy market with Nanoplasty™ and Percuplasty™ Systems
The company provided 2025 revenue guidance of $224-230 million (7-10% growth) and expects to achieve breakeven Adjusted EBITDA for full-year 2025.
Treace Medical Concepts (NasdaqGS: TMCI), a medical technology company specializing in surgical treatments for bunions and midfoot deformities through its Lapiplasty® and Adductoplasty® Procedures, has announced it will release its fourth quarter and full-year 2024 financial results after market close on February 27, 2025.
The company will host a conference call with management at 4:30 pm ET on the same day to discuss the results. Interested investors can register to receive dial-in numbers and a unique pin to participate and ask questions. A live and archived webcast will be available on the company's investor relations website.
Treace Medical Concepts (NASDAQ: TMCI) has announced the successful completion of first surgical cases using its new SpeedAkin™ Anatomic Compression Implant. This implant expands the capabilities of their SpeedPlate™ fixation platform, specifically designed for Akin osteotomies - corrective procedures commonly performed during bunion surgery.
The SpeedAkin™ implant features dynamic titanium compression to stabilize Akin osteotomies during healing, offering an anatomically contoured fixation solution that eliminates potential nickel allergy reactions associated with nitinol staples. This development complements Treace's existing bunion treatment portfolio, which includes their flagship Lapiplasty® and Adductoplasty® Procedures.
Treace Medical Concepts (NASDAQ: TMCI) has released preliminary, unaudited financial results for Q4 and full-year 2024. The company reported preliminary Q4 revenue between $68.4-68.8 million, representing approximately 10% growth compared to Q4 2023. Full-year 2024 preliminary revenue reached $209.0-209.4 million, showing roughly 12% growth year-over-year and aligning with previous guidance of $204-211 million.
The company added approximately 280 new active surgeons in 2024, ending the year with about 3,135 active surgeons, a 10% increase from 2023. This represents approximately 31% of the estimated 10,000 U.S. surgeons performing bunion surgery. The company plans to provide 2025 financial guidance during its Q4 2024 earnings call scheduled for February 27, 2025.
Treace Medical Concepts (NasdaqGS: TMCI), a pioneer in bunion and midfoot deformity surgical treatments through its Lapiplasty® and Adductoplasty® Procedures, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference.
CEO John T. Treace will deliver a presentation on Tuesday, January 14, 2025, at 9:00 am PT. The company will provide a live webcast of the fireside chat, which will be accessible through their investor relations website at https://investors.treace.com/.
The company maintains regular updates for investors through their website's Investor Relations section at www.treace.com, where important information is routinely posted for stakeholders and potential investors.
Treace Medical Concepts (TMCI) announced the market release of its Percuplasty™ Percutaneous 3D Bunion Correction® System, marking the company's second entry into the metatarsal osteotomy segment. This segment represents approximately 70% of the 450,000 annual bunion surgeries in the U.S.
The Percuplasty™ System offers a minimally invasive approach through percutaneous incisions, designed to minimize post-operative pain and accelerate recovery. This launch follows the Nanoplasty™ System release, expanding Treace's portfolio in the $5B+ US bunion market. Full commercialization is expected in the second half of 2025.
